600285.SH
羚锐制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 19.58
+0.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.0B | 3.9B | 3.5B | 3.3B | 3.0B |
| Cost of Revenue | 778.0M | 769.6M | 846.6M | 884.4M | 832.1M |
| Gross Profit | 3.2B | 3.1B | 2.7B | 2.4B | 2.2B |
| Operating Expenses | |||||
| R&D Expense | 177.8M | 169.1M | 131.5M | 109.7M | 125.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 214.4M | 215.6M | 166.7M | 174.2M | 169.4M |
| Selling & Marketing Expense | 1.9B | 1.8B | 1.6B | 1.5B | 1.4B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.3B | 2.3B | 1.9B | 1.8B | 1.8B |
| Cost and Expenses | 3.1B | 3.0B | 2.8B | 2.7B | 2.6B |
| Operating Income (EBIT) | 918.8M | 887.3M | 810.3M | 656.3M | 517.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 911.3M | 879.5M | 827.6M | 653.0M | 517.0M |
| Income Tax Expense | 118.2M | 117.0M | 105.0M | 84.9M | 51.7M |
| Bottom Line | |||||
| Net Income | 789.0M | 759.5M | 722.6M | 568.1M | 465.3M |
| Earnings from Cont. Ops | 793.2M | 762.4M | 722.6M | 568.1M | 465.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 789.0M | 759.5M | 722.6M | 568.1M | 465.3M |
| Per Share | |||||
| Basic EPS | CN¥1.39 | CN¥1.34 | CN¥1.29 | CN¥1.01 | CN¥0.84 |
| Diluted EPS | CN¥1.39 | CN¥1.34 | CN¥1.28 | CN¥1.00 | CN¥0.82 |
| Revenue Per Share | CN¥6.99 | CN¥6.80 | CN¥6.24 | CN¥5.90 | CN¥5.39 |
| Shares | |||||
| Basic Shares Outstanding | 566.3M | 566.8M | 561.4M | 561.4M | 556.6M |
| Diluted Shares Outstanding | 566.3M | 566.8M | 561.4M | 561.4M | 556.6M |
| Profitability Metrics | |||||
| EBITDA | — | 985.2M | 884.7M | 737.0M | 594.3M |
| D&A | — | 97.9M | 74.4M | 80.7M | 77.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026